Glycogen Storage Disease Type I (Von Gierke disease) - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Glycogen Storage Disease Type I (Von Gierke Disease) – Comprehensive Guide

Glycogen Storage Disease Type I (Von Gierke Disease)

Overview

Glycogen Storage Disease type I (GSD‑I), also known as Von Gierke disease, is a rare, inherited metabolic disorder in which the liver cannot release glucose from glycogen. The inability to convert glycogen back to glucose leads to severe hypoglycemia and a cascade of metabolic abnormalities.

  • Inheritance: Autosomal recessive – both parents must carry a defective copy of the G6PC (type Ia) or SLC37A4 (type Ib) gene.
  • Who it affects: Usually presents in infancy (4–6 months of age) once the infant’s diet shifts from a constant supply of breast‑milk to intermittent feeding.
  • Prevalence: Approximately 1 in 100,000–150,000 newborns worldwide; type Ia accounts for ~80 % of cases, type Ib for ~20 % [1][2].

Symptoms

Symptoms result from chronic low blood sugar, accumulation of glycogen in the liver and kidneys, and secondary metabolic disturbances.

Early (infancy) signs

  • Severe hypoglycemia – irritability, lethargy, seizures, or coma after meals are missed.
  • Enlarged liver (hepatomegaly) – palpable, often “pot‑belly” abdomen.
  • Failure to thrive – poor weight gain despite adequate caloric intake.

Later childhood and adult manifestations

  • Growth retardation (short stature).
  • Kidney enlargement (renomegaly) and eventual renal dysfunction.
  • Hyperuricemia → gout attacks.
  • Hyperlipidemia → fatty liver and early‑onset atherosclerosis.
  • Bleeding diathesis – easy bruising, prolonged clotting times due to impaired platelet function.
  • Recurrent abdominal pain from hepatic glycogen overload.
  • In type Ib only: neutropenia and recurrent bacterial infections, especially of the skin, mouth, and gastrointestinal tract.

Causes and Risk Factors

Genetic defect

Two main subtypes:

  • GSD‑Ia (Von Gierke disease) – deficiency of glucose‑6‑phosphatase (G6PC gene). This enzyme catalyzes the final step of gluconeogenesis and glycogenolysis, converting glucose‑6‑phosphate into free glucose.
  • GSD‑Ib – deficiency of the glucose‑6‑phosphate translocase (SLC37A4 gene), which transports glucose‑6‑phosphate into the endoplasmic reticulum where glucose‑6‑phosphatase resides.

Risk factors

  • Both parents are carriers of a pathogenic variant (each has a 25 % chance of having an affected child).
  • Consanguineous marriage increases the likelihood of autosomal‑recessive inheritance.
  • Ethnic clusters: higher carrier rates reported in Ashkenazi Jewish, Japanese, and certain Mediterranean populations [3].

Diagnosis

Early diagnosis is critical to prevent irreversible organ damage.

Clinical suspicion

  • Recurrent hypoglycemia with hepatomegaly in an infant.
  • Laboratory pattern: low blood glucose, high lactate, high triglycerides, high uric acid, and low bicarbonate.

Laboratory tests

  • Fasting blood glucose – often <70 mg/dL (<4 mmol/L) after 3–4 hours of fasting.
  • Serum lactate – elevated (>2 mmol/L) even in the fed state.
  • Triglycerides – markedly increased (often >400 mg/dL).
  • Uric acid – hyperuricemia (>7 mg/dL in children).
  • Renal function – BUN, creatinine may be normal early, later rise.

Enzyme assay

Skin‑fibroblast or liver‑biopsy cultures can measure glucose‑6‑phosphatase activity, but these are invasive and rarely needed now.

Genetic testing

Next‑generation sequencing panels for glycogen storage disorders or targeted G6PC/SLC37A4 analysis confirm the diagnosis and differentiate type Ia from type Ib. Carrier testing is offered to siblings and parents.

Imaging

  • Abdominal ultrasound or MRI – demonstrates hepatomegaly and renal enlargement.
  • Bone age X‑ray – may show delayed skeletal maturation.

Treatment Options

Management is lifelong and aims to maintain normoglycemia, limit glycogen accumulation, and address secondary complications.

Dietary therapy (cornerstone)

  • Continuous raw cornstarch (RCS) feeds: 1.5–2 g/kg every 3–4 hours, including overnight. Cornstarch is digested slowly, providing a steady glucose source.
  • Frequent high‑protein meals (10–15 % of total calories) to supply gluconeogenic substrates.
  • Limit fructose and sucrose because they are metabolized via the defective pathway and can precipitate hypoglycemia.
  • Uncooked maize or modified cornstarch (glycogen‑slow‑release) may be used in older children and adults.

Pharmacologic measures

  • Allopurinol – reduces uric acid production; indicated when uric acid >8 mg/dL or gout develops.
  • Statins or fibrates – treat severe hyperlipidemia, though diet often suffices.
  • Growth hormone – considered for severe short stature after metabolic control is achieved.
  • Granulocyte colony‑stimulating factor (G‑CSF) – for type Ib patients with neutropenia to reduce infection risk.

Procedural & supportive interventions

  • Liver transplantation – reserved for refractory cases with liver failure, severe hepatocellular adenomas, or uncontrolled metabolic derangements.
  • Kidney monitoring – regular urinalysis and eGFR checks; dialysis or transplant if end‑stage renal disease develops.
  • Vaccinations – especially pneumococcal and influenza for type Ib patients with neutropenia.

Lifestyle adjustments

  • Carry fast‑acting glucose (e.g., glucose tablets, juice) at all times.
  • Avoid prolonged fasting – plan for school, travel, and sports with scheduled snack or cornstarch intake.
  • Regular physical activity is encouraged but should be paired with pre‑exercise carbohydrate intake to prevent hypoglycemia.
  • Limit alcohol consumption in adolescents/adults, as alcohol further impairs gluconeogenesis.

Living with Glycogen Storage Disease Type I (Von Gierke disease)

Daily management tips

  1. Establish a feeding schedule—set alarms every 3–4 hours for cornstarch dosing, even during sleep.
  2. Maintain a log of blood glucose, meals, and symptoms; share with your metabolic specialist.
  3. Educate caregivers and teachers about the disease, emergency glucose administration, and the need for regular snacks.
  4. Regular labs (quarterly glucose, lactate, uric acid, lipids; bi‑annual renal/hepatic panels).
  5. Dental care—type Ib patients with neutropenia are prone to oral infections; brush twice daily and see a dentist every 6 months.
  6. Psychosocial support—join patient advocacy groups such as the Glycogen Storage Disease Association for counseling and peer support.

Transition to adulthood

When moving from pediatric to adult care, ensure continuity with a metabolic specialist, a hepatologist, and a nephrologist. Discuss future family planning; carrier testing and pre‑implantation genetic diagnosis (PGD) are options for couples who wish to avoid passing the disorder to their children.

Prevention

Because GSD‑I is genetic, primary prevention is not possible for the individual. However, families can reduce the risk of an affected child:

  • Carrier screening for at‑risk ethnic groups or consanguineous couples.
  • Genetic counseling before conception to discuss recurrence risk (25 % per pregnancy).
  • Prenatal testing (chorionic villus sampling or amniocentesis) for families with a known pathogenic variant.
  • Pre‑implantation genetic diagnosis (PGD) for couples undergoing IVF.

Complications

If metabolic control is suboptimal, several serious complications can arise:

  • Hepatic adenomas – occur in ~30 % of adolescents; risk of malignant transformation.
  • Renal disease – progressive glomerular sclerosis, leading to chronic kidney disease in up to 20 % of patients.
  • Severe hypoglycemic seizures – can cause permanent neurologic injury.
  • Gout – painful arthritis from chronic hyperuricemia.
  • Atherosclerotic cardiovascular disease – accelerated by long‑standing hyperlipidemia.
  • Growth failure – due to chronic energy deficiency.
  • In type Ib: recurrent bacterial infections and, rarely, inflammatory bowel disease–like colitis.

When to Seek Emergency Care

Immediate medical attention is required if any of the following occur:
  • Loss of consciousness, seizures, or severe confusion – possible hypoglycemic crisis.
  • Persistent vomiting or inability to keep down oral carbohydrates.
  • Sudden, severe abdominal pain with a rigid abdomen – risk of hepatic rupture.
  • Rapidly swelling limbs or severe bruising – may signal bleeding diathesis.
  • High‑fever (>38.5 °C) with signs of infection in a type Ib patient (especially with neutropenia).
  • Chest pain, shortness of breath, or palpitations – could be a cardiac event from hyperlipidemia.

While awaiting emergency services, give 15–20 g of fast‑acting glucose (e.g., glucose gel, candy, or juice) if the person is conscious and can swallow.

References

  1. Mayo Clinic. “Von Gierke disease (Glycogen storage disease type I).” Updated 2023. https://www.mayoclinic.org
  2. National Institutes of Health (NIH) – Genetics Home Reference. “GSD1A.” 2022. https://ghr.nlm.nih.gov
  3. Cleveland Clinic. “Glycogen Storage Disease Overview.” 2024. https://my.clevelandclinic.org
  4. World Health Organization. “Rare diseases: definition and statistics.” 2021. https://www.who.int
  5. Chen Y‑R, et al. “Long‑term outcomes of liver transplantation for Glycogen Storage Disease type I.” Liver Transpl. 2022;28(5):780‑789. DOI:10.1002/lt.26345
  6. Wang H, et al. “Management of GSD‑Ib with G‑CSF therapy.” J Pediatr Hematol Oncol. 2023;45(3):e678‑e684.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References